Celgene places $1bn bet on Juno Therapeutics – FT.com
Celgene, one of the biggest names in the US biotech industry, has invested $1bn in Juno Therapeutics, as part of a wide-ranging partnership that is seen as a strong vote of confidence in a new generation of experimental cancer treatments. Juno
Source: www.ft.com